

Brain endothelial LRP1 maintains blood brain-barrier integrity

Steffen Storck (✉ storck@uni-mainz.de)

Universitätsmedizin der Johannes Gutenberg-Universität Mainz <https://orcid.org/0000-0002-6965-2264>

Claus Pietrzik

Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Research Article

Keywords: Blood-brain barrier integrity, low-density lipoprotein receptor-related protein 1 (LRP1), P-24 glycoprotein/Abcb1 (P-gp), tight junctions, matrix metalloproteinases (MMPs), cyclophilin A 25

Posted Date: February 24th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-233246/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 Brain endothelial LRP1 maintains blood brain-barrier integrity

2 Steffen E. Storck and Claus U. Pietrzik

3 Institute for Pathobiochemistry, University Medical Center of the Johannes Gutenberg-University, Mainz,
4 Germany.

5 Correspondence:

6 Claus U Pietrzik, Molecular Neurodegeneration, Institute for Pathobiochemistry, University Medical Center of
7 the Johannes Gutenberg University of Mainz, Duesbergweg 6, Mainz 55099, Germany. Email: pietrzik@uni-
8 mainz.de

9 Steffen E Storck, Molecular Neurodegeneration, Institute for Pathobiochemistry, University Medical Center of
10 the Johannes Gutenberg University of Mainz, Duesbergweg 6, Mainz 55099, Germany. Email: storck@uni-
11 mainz.de

12

13 **Abstract**

14 **The entry of blood-borne molecules into the brain is restricted by the blood brain-barrier (BBB).**
15 **Various physical, transport and immune properties tightly regulate molecule movement between**
16 **the blood and the brain to maintain brain homeostasis. A recent study utilizing a pan-endothelial,**
17 **constitutive *Tie2-Cre* showed that paracellular passage of blood proteins into the brain is governed**
18 **by endocytic and cell signaling protein low-density lipoprotein receptor–related protein 1 (LRP1).**
19 **Taking advantage of conditional *Slco1c1-CreER^{T2}* specific to CNS endothelial cells and choroid plexus**
20 **epithelial cells we now supplement previous results and show that brain endothelial *Lrp1* ablation**
21 **results protease-mediated tight junction degradation, P-glycoprotein (P-gp) reduction and a loss of**
22 **BBB integrity.**

23 **Keywords**

24 Blood-brain barrier integrity, low-density lipoprotein receptor-related protein 1 (LRP1), P-
25 glycoprotein/Abcb1 (P-gp), tight junctions, matrix metalloproteinases (MMPs), cyclophilin A

26

27 **Background**

28 Neuronal function requires tight regulation of the cerebral microenvironment, which is achieved
29 through specialized brain barriers such as the blood-brain barrier (BBB) (1). Dysfunction of these
30 barriers lead to neuronal degeneration and cognitive decline (2). A recent report demonstrated that
31 global endothelial loss of the endocytic and cell signaling protein low-density lipoprotein receptor–
32 related protein 1 (LRP1) utilizing a constitutive *Tie2-Cre* line results in increased brain penetration of
33 blood-borne molecules such as IgG and fibrinogen, progressive neuronal damage and behavioral
34 deficits in mice (3). Nikolakopoulou and colleagues identified a cyclophilin A–matrix metalloproteinase
35 (MMP)-9 pathway in the *Lrp1*-deficient endothelium underlying BBB impairment: Deletion of LRP1
36 elevates cyclophilin A levels, which increases metalloproteinase-9-mediated tight junction protein
37 degradation which allows the paracellular brain penetration of blood proteins leading to neuronal
38 damage. Notable, LRP1 gene therapy targeting the BBB partially reversed vascular leakage, neuronal
39 damage and behavioral deficits in mice.

40 Whilst these findings have broad implications for understanding how loss of endothelial LRP1
41 contributes to brain pathology, some questions for the audience remain. It is incompletely described
42 how transcellular passage of molecules contributes to brain leakage of blood-borne molecules. Tight
43 junctions are not the only regulator of BBB permeability. The authors did not see any effects of *Lrp1*
44 deletion on pericyte coverage or endothelial MFSD2a and GLUT1 levels, known modulators of
45 transcellular transport processes (4, 5). However, endothelial solute and adenosine triphosphate
46 binding cassette (ABC) efflux transporters such P-glycoprotein (P-gp, also known as ABCB1 or MDR1)
47 limit the entry of many xenobiotics and endogenous molecules that might damage neuronal cells (6-
48 8). ABC transporter expression is regulated by peroxisome proliferator-activated receptors (PPAR)
49 signaling (9). Notably, it has been shown that endothelial LRP1 is a coactivator of the nuclear receptor
50 PPAR γ and directly participates in gene transcription (10) . If the PPAR signaling co-activator LRP1 is
51 missing, ABC transporter levels could be altered. So, it is possible that, in addition to the described

52 paracellular leakage described by Nikolakopoulou and colleagues, transcellular passage is altered due
53 to a change in efflux transporters such as P-gp. Therefore, the increased permeability in *Lrp1^{lox/lox}; Tie2-*
54 *Cre* described in the recent paper would only be the result of increased paracellular passage through
55 a lack of tight junctional proteins.

56 The second question remains regards the specificity of the *Cre* mouse line that was used in the study:
57 how does a constitutive and global deletion of *Lrp1* in all endothelial cells contribute to the brain-
58 related findings described in Nikolakopoulou et al.? In the study, the authors used a pan-endothelial
59 expression of the *Cre* (*Tie2-Cre*) that targets all peripheral and CNS vasculature during development as
60 well as adulthood. However, LRP1 is expressed in all endothelial cells throughout the organism and is
61 involved in many endocytic and cell signaling events during development as well as angiogenesis (11,
62 12). Therefore, *Tie2-Cre*-mediated *Lrp1* deletion could have adverse off-target effects that contribute
63 to the described pathology. Interestingly, we collected data showing similar results in mice using a
64 conditional, tamoxifen-inducible *Slco1c1-CreER^{T2}* not targeting peripheral vasculature and allowing the
65 time-specific deletion of LRP1 in the vasculature of the brain (13).

66 **Results**

67 *Slco1c1* is highly enriched in CNS vasculature over peripheral vasculature (14) and therefore, allowing
68 *Cre*-induction specifically in brain endothelium and choroid plexus epithelium (13). Utilizing spatial
69 activation of *Cre* in brain endothelial cells only prevents potential side effects by not targeting
70 peripheral vasculature as in pan-endothelial *Cre*-lines. In contrast to a constitutive, global *Tie2-Cre*-
71 driven promoter (15), temporal induction of gene deletion in adult *Slco1c1-Cre ER^{T2}* mice can rule out
72 any potential off-target effects of *Lrp1* deletion during development.

73 Originally, we found that in freshly isolated brain endothelial cells of *Lrp1^{lox/lox}; Slco1c1-CreER^{T2}* mice,
74 claudin-5 and occludin protein levels were markedly reduced compared to littermates (Fig. 1A). At the
75 same time, the levels of cyclophilin A, an activator of a MMP-mediated tight junction degradation
76 pathway in endothelial cells (3), were significantly elevated (Fig. 1B). Utilizing primary brain endothelial

77 cells from *Lrp1^{lox/lox}; Slco1c1-CreER^{T2}* mice we found higher MMP activity (Fig. 2A), lower
78 transendothelial resistance (Fig. 2B) measured by impedance spectroscopy along with increased ¹⁴C-
79 inulin permeability across an endothelial monolayer compared littermate control cells (Fig. 2C). These
80 results suggested that elevated MMP activity in *Lrp1^{lox/lox}; Slco1c1-CreER^{T2}* endothelial cells resulted in
81 enhanced endothelial permeability due to tight junction degradation.

82 In in the cerebrospinal fluid (CSF) of *Lrp1^{lox/lox}; Slco1c1-CreER^{T2}* mice, we detected substantially
83 increased IgG levels (Fig. 3A) and a higher brain water content (Fig. 3B), another measure of BBB
84 integrity (16, 17). At the same time, we found P-gp decreased (Fig. 1C, also reported in (18)). It remains
85 to be determined by future studies if other transporter levels are affected too and what the functional
86 consequences on the loss of P-gp are for brain penetration or xenobiotics in *Lrp1^{lox/lox}; Slco1c1-CreER^{T2}*
87 mice. However, a recent study shows a direct effect on brain uptake of P-gp substrate rhodamine123
88 upon changes in P-gp transcript levels (19). Collectively, these data suggest that BBB permeability is
89 increased by paracellular as well as transcellular mechanisms when endothelial LRP1 is absent. In
90 *Lrp1^{lox/lox}; Slco1c1-CreER^{T2}* mice both body and brain weight were significantly reduced when the
91 animals were housed on a constant tamoxifen-supplemented chow (Fi. 4A+B) suggesting that lack of
92 endothelial LRP1 impairs homeostasis and metabolism as also suggested by earlier studies (10).

93 Unexpectedly, as reported earlier we did not find any differences in BBB integrity in *Lrp1^{lox/lox}; Slco1c1-
94 CreER^{T2}* at 8 months (20). After an initial 7-days treatment with tamoxifen at 8 weeks of age, the mice
95 were housed on a normal chow lacking tamoxifen. Given the massive damage occurring to CNS
96 vasculature reported here and in the study by Nikolakopoulou and colleagues (3), we are now
97 questioning, whether a long-term brain endothelial LRP1 deletion will prevail over time in a conditional
98 system in aged mice when the driving Cre is not constitutively expressed and only a single treatment
99 of tamoxifen early in adulthood is applied as it was done in the study. Vascular damage recruits bone
100 marrow-derived endothelial progenitor cells (sometimes also referred as circulating angiogenic cells)
101 from the periphery for vascular repair (21-23). Different from a constitutive model, a conditional model
102 could therefore re-gain gene expression over time by replacement of damaged endothelial cells with

103 peripheral LRP1 expressing blood-circulating cells and therefore mask the initial effects of the initial
104 knockout. Further studies are needed to fully decipher the biological mechanisms underlying the
105 effects seen in *Lrp1^{lox/lox}; Slco1c1-CreER^{T2}*.

106 Collectively, the data suggests that many of the results shown by Nikolakopoulou and colleagues can
107 be independently reproduced by using a conditional knockout model. It seems that spatial and
108 temporal control of endothelial LRP1 recapitulates the finding of a global, constitutive endothelial
109 knockout. However, it remains to be demonstrated whether neuronal damage as described in
110 Nikolakopoulou et al. are merely the results of increased paracellular influx of blood-borne molecules
111 into the brain or altered transcellular movement of molecules due to changes in ABC transporter
112 expression contribute to brain pathology.

113

114 **Methods**

115 *Mice*

116 *Lrp1^{lox/lox}; Slco1c1-CreER^{T2}* (20) and littermate *Lrp1^{lox/lox}* controls were housed under a 12-h light-dark
117 cycle with water and rodent chow ad libitum. For all studies both sexes were used. Brain and body
118 weight was analyzed with 12 months of age.

119 *Antibodies*

120 Rabbit anti- β -actin (A2066, Sigma-Aldrich, 1:1,000), Rabbit anti-claudin-5 (34-1600, Invitrogen,
121 1:1,000), Mouse anti-occludin (33-1500, Invitrogen, 1:1,000), H-241 rabbit anti-Mdr (sc-8313, WB:
122 1:1000 – detects MDR1&MDR3 mouse/rat/human), rabbit anti cyclophilin A (ab3563, Abcam,
123 1:1,000), 1704 rabbit anti-LRP1 (WB: 1: 10,000) was generated as described before (24), HRP-
124 conjugated donkey anti-mouse (715-035-151, Jackson Immuno Research, 1:5,000), HRP-conjugated
125 goat anti-rabbit (A5278, Sigma-Aldrich, 1:10,000).

126

127 *Isolation and cultivation of primary mouse brain capillary endothelial cells*

128 Primary mouse brain capillary endothelial cells were isolated from 8-week-old mice as described
129 previously with minor modifications (20, 25). In brief, mice were sacrificed by cervical dislocation,
130 meninges were removed, cortices were pooled and mechanically dissociated, followed by a digest with
131 a mixture of 0.75 mg/ml collagenase CLS2 (Worthington, Lakewood, NJ, USA) and 10 U/ml DNaseI
132 (Sigma-Aldrich, Schnelldorf, Germany) in DMEM (Gibco, Darmstadt, Germany) at 37°C on a shaker set
133 at 1000g for 1 h. The pellet was resuspended in 20% BSA-DMEM (w/v) and centrifuged at 1000g for
134 20 min to remove myelin. The pellet was further digested with 1 mg/mL collagenase-dispase (Roche,
135 Mannheim, Germany) and 10 U/mL DNase in DMEM at 37°C on a shaker for 1 h. Endothelial capillaries
136 were separated on a 33% continuous Percoll (GE Healthcare, Munich, Germany) gradient, collected,
137 and subjected to cell lysis or plated on 24-well transwell filters (pore size, 0.4 µm; surface area, 33.6
138 mm²; Greiner Bio-One) coated with 0.4 mg/mL collagen IV and 0.1 mg/mL fibronectin (both from
139 Sigma-Aldrich, Schnelldorf, Germany). Cultures were maintained in DMEM supplemented with 20%
140 plasma-derived bovine serum (First Link, Birmingham, UK), 100 U/mL penicillin and 100 µg/mL
141 streptomycin, 2 mM L-glutamine (all from Gibco, Darmstadt, Germany), 4 µg/mL puromycin (Alexis,
142 Loerrach, Germany) and 30 µg/ml endothelial cell growth supplement (Sigma-Aldrich, Schnelldorf,
143 Germany) at 37°C and 5% CO₂.

144 For immunoblot analysis, isolated capillary fragments were solubilized in lysis buffer (50 mM TrisOH,
145 150 mM NaCl, 0.02% [w/v] NaN₃, 1% [v/v] Nonidet P-40 supplemented with a cocktail of phosphatase
146 and proteinase inhibitors [PhosStop, Complete, Roche Applied Science]). Homogenates were
147 centrifuged for 20 min at 15,000g, and the supernatant was collected. 10 µg of capillary lysate was
148 separated on 4–12% Bis-Tris gels (NuPAGE™, Invitrogen) gels by SDS-PAGE, transferred onto
149 nitrocellulose membranes (Millipore).

150 *Transendothelial electrical resistance and permeability studies*

151 TEER and capacitance of cells were measured automatically every hour by impedance spectroscopy
152 with the cellZscope device. When capacitance values were between 1.0 and 0.8 $\mu\text{F}/\text{cm}^2$, indicating a
153 confluent monolayer of cells, the TEER values were measured. Permeability to [C^{14}]-inulin (Perkin-
154 Elmer, Waltham, MA, USA) was analyzed as described previously (26).

155 *MMP activity*

156 MMP activity was measured from equal volumes of cell-free supernatant from confluent endothelial
157 cells grown on transwell filters as described above. 3 hours after incubation with OMNIMMP®
158 fluorogenic substrate (Enzo) at 37°C, fluorescence of the cleaved substrate was measured at an
159 emission/excitation wavelength of 280/360 nm according to the manufactures' protocol.

160 *CSF isolation*


161 Blood-free CSF of 20-week-old mice were taken by puncture of the cisterna magna as described
162 previously (20). After centrifugation at $900 \times g$ for 10 min at 4°C, 4 μl of cell-free CSF were diluted in
163 water and mixed with equal amounts of 2 \times RotiLoad (Carl Roth, Karlsruhe, Germany). The IgG protein
164 levels in CSF were determined using a secondary anti-mouse antibody.

165 *Brain water content*

166 Brain water content from 20-week-old mice was determined as described previously (17). Mice were
167 anesthetized, sacrificed by cervical dislocation, and the brain was immediately removed, weighed and
168 then dried overnight at 100°C. The dried brain was re-weighed and the brain water content calculated
169 as $(\text{wet weight} - \text{dry weight}) \times 100 / \text{wet weight}$.

170

171 **Figures**



172


173 **Fig.1: Reduced levels of tight junction proteins and P-gp after *Lrp1* CNS endothelial loss. (A)**

174 Immunoblotting for occludin, and claudin 5 (B) cyclophilin A and (C) P-gp in isolated brain endothelial

175 cells and their relative abundance compared with β -actin (loading control) of 2-month-old *Lrp1^{lox/lox}*;


176 *Slco1c1-CreER^{T2}* mice and *Lrp1^{lox/lox}* littermate controls. Mean \pm SEM, n = 3 isolates/group. Significance

177 was determined by Student's t test




179 **Fig.2: Enhanced MMP activity after *Lrp1* deletion increases permeability in cultured primary brain**
 180 **endothelial cells.** (A) relative MMP activity, (B) transendothelial resistance and (C) ^{14}C -inulin
 181 permeability of primary brain endothelial cells isolated from of 2-month-old *Lrp1*^{lox/lox}; *Slco1c1-CreER*^{T2}
 182 mice and *Lrp1*^{lox/lox} littermate controls. Primary brain endothelial cells were cultivated on transwell
 183 inserts in the cellZcope device. Cell or supernatant were used for subsequent studies when confluent.
 184 Mean \pm SEM. B and C are data from 3 independent isolates. Significance was determined by Student's
 185 t test.

186



188 **Fig.3: Enhanced BBB permeability after *Lrp1* CNS endothelial loss.** (A) Immunoblotting and
 189 quantification for IgG in 3 μL cell- and blood-free CSF and (B) brain water content (calculated as [wet
 190 weight–dry weight] \times 100/wet weight) in 20-month-old *Lrp1*^{lox/lox}; *Slco1c1-CreER*^{T2} mice and *Lrp1*^{lox/lox}
 191 littermate controls. Mean \pm SEM, n= 4 (in A) and 7 (in B) mice/group. Significance was determined by
 192 Student's t test.



193

194 **Fig.4 Reduced brain body and brain weight upon brain endothelial *Lrp1* deletion.** (A) Brain (n=7+10
 195 mice, left to right) and (B) body weight (n=8+11 mice, left to right) in 12-month-old *Lrp1*^{lox/lox}; *Slco1c1-*
 196 *CreER*^{T2} mice and *Lrp1*^{lox/lox} littermate controls. Mean ± SEM. Significance was determined by Student's
 197 t test.

198

199 List of abbreviations

200 adenosine triphosphate binding cassette (ABC)

201 blood brain-barrier (BBB)

202 cerebrospinal fluid (CSF)

203 low-density protein receptor-related protein 1 (LRP1)

204 matrix metalloproteinase (MMP)

205 peroxisome proliferator-activated receptors (PPAR)

206 p-glycoprotein (P-gp)

207

208 Declarations

209 *Ethics approval and consent to participate*

210 All animal studies were conducted in compliance with European and German guidelines for the care
211 and use of laboratory animals and were approved by the Central Animal Facility of the University of
212 Mainz and the ethical committee on animal care and use of Rhineland-Palatinate, Germany.

213 *Consent for publication*

214 Not applicable.

215 *Competing interests*

216 The authors declare that they have no competing interests.

217 *Availability of data and materials*

218 All data generated or analysed during this study are included in this published article.

219 *Funding*

220 The project was funded by grants of the Deutsche Forschungsgemeinschaft (PI 379/8-3) and the IMI
221 EU grant (Im2pact) to C.U.P. and the intramural funding program of the University Medical Center of
222 the Johannes-Gutenberg University Mainz to S.E.S.

223 *Authors' contributions*

224 SES designed the studies, conducted the experiments, and wrote the manuscript. CUP supervised the
225 experimental design and entire work of the manuscript. Both authors read and approved the final
226 manuscript.

227 *Acknowledgements*

228 The authors thank Johanna Wesselowski and Roswitha Nehrbaß for excellent technical assistance.

229

230 **References**

- 231 1. Profaci CP, Munji RN, Pulido RS, Daneman R. The blood-brain barrier in health and disease:
232 Important unanswered questions. *The Journal of experimental medicine*. 2020;217(4). Epub
233 2020/03/27.
- 234 2. Storck SE, Pietrzik CU. The Blood brain-barrier and its role in Alzheimer's disease. *Neuroforum*
235 2018;24(4):A197-A205. Epub 09.11.2018.
- 236 3. Nikolakopoulou AM, Wang Y, Ma Q, Sagare AP, Montagne A, Huuskonen MT, et al. Endothelial
237 LRP1 protects against neurodegeneration by blocking cyclophilin A. *The Journal of experimental*
238 *medicine*. 2021;218(4). Epub 2021/02/04.
- 239 4. Daneman R, Zhou L, Kebede AA, Barres BA. Pericytes are required for blood-brain barrier
240 integrity during embryogenesis. *Nature*. 2010;468(7323):562-6. Epub 2010/10/15.
- 241 5. Ben-Zvi A, Lacoste B, Kur E, Andreone BJ, Mayshar Y, Yan H, et al. Mfsd2a is critical for the
242 formation and function of the blood-brain barrier. *Nature*. 2014;509(7501):507-11. Epub 2014/05/16.
- 243 6. Wolf A, Bauer B, Hartz AM. ABC Transporters and the Alzheimer's Disease Enigma. *Frontiers in*
244 *psychiatry*. 2012;3:54. Epub 2012/06/08.
- 245 7. Hartz AM, Bauer B. ABC transporters in the CNS - an inventory. *Current pharmaceutical*
246 *biotechnology*. 2011;12(4):656-73. Epub 2010/12/02.
- 247 8. Hartz AM, Bauer B. Regulation of ABC transporters at the blood-brain barrier: new targets for
248 CNS therapy. *Molecular interventions*. 2010;10(5):293-304. Epub 2010/11/04.
- 249 9. Apostoli AJ, Nicol CJ. PPAR Medicines and Human Disease: The ABCs of It All. *PPAR research*.
250 2012;2012:504918. Epub 2012/08/25.
- 251 10. Mao H, Lockyer P, Li L, Ballantyne CM, Patterson C, Xie L, et al. Endothelial LRP1 regulates
252 metabolic responses by acting as a co-activator of PPARgamma. *Nature communications*.
253 2017;8:14960. Epub 2017/04/11.
- 254 11. Mao H, Lockyer P, Townley-Tilson WH, Xie L, Pi X. LRP1 Regulates Retinal Angiogenesis by
255 Inhibiting PARP-1 Activity and Endothelial Cell Proliferation. *Arterioscler Thromb Vasc Biol*.
256 2016;36(2):350-60.

- 257 12. Mao H, Xie L, Pi X. Low-Density Lipoprotein Receptor-Related Protein-1 Signaling in
258 Angiogenesis. *Front Cardiovasc Med.* 2017;4:34.
- 259 13. Ridder DA, Lang MF, Salinin S, Roderer JP, Struss M, Maser-Gluth C, et al. TAK1 in brain
260 endothelial cells mediates fever and lethargy. *The Journal of experimental medicine.*
261 2011;208(13):2615-23. Epub 2011/12/07.
- 262 14. Daneman R, Zhou L, Agalliu D, Cahoy JD, Kaushal A, Barres BA. The mouse blood-brain barrier
263 transcriptome: a new resource for understanding the development and function of brain endothelial
264 cells. *PloS one.* 2010;5(10):e13741.
- 265 15. Kisanuki YY, Hammer RE, Miyazaki J, Williams SC, Richardson JA, Yanagisawa M. Tie2-Cre
266 transgenic mice: a new model for endothelial cell-lineage analysis in vivo. *Dev Biol.* 2001;230(2):230-
267 42.
- 268 16. Keep RF, Hua Y, Xi G. Brain water content. A misunderstood measurement? *Translational*
269 *stroke research.* 2012;3(2):263-5. Epub 2012/08/14.
- 270 17. Gindorf M, Storck SE, Ohler A, Scharfenberg F, Becker-Pauly C, Pietrzik CU. Meprin beta: A
271 novel regulator of blood-brain barrier integrity. *Journal of cerebral blood flow and metabolism : official*
272 *journal of the International Society of Cerebral Blood Flow and Metabolism.* 2020:271678X20905206.
273 Epub 2020/02/18.
- 274 18. Storck SE, Hartz AMS, Bernard J, Wolf A, Kachlmeier A, Mahringer A, et al. The concerted
275 amyloid-beta clearance of LRP1 and ABCB1/P-gp across the blood-brain barrier is linked by PICALM.
276 *Brain, behavior, and immunity.* 2018;73:21-33. Epub 2018/07/25.
- 277 19. Pulido RS, Munji RN, Chan TC, Quirk CR, Weiner GA, Weger BD, et al. Neuronal Activity
278 Regulates Blood-Brain Barrier Efflux Transport through Endothelial Circadian Genes. *Neuron.*
279 2020;108(5):937-52 e7.
- 280 20. Storck SE, Meister S, Nahrath J, Meissner JN, Schubert N, Di Spiezio A, et al. Endothelial LRP1
281 transports amyloid-beta(1-42) across the blood-brain barrier. *The Journal of clinical investigation.*
282 2016;126(1):123-36. Epub 2015/12/01.

- 283 21. Tenreiro MM, Ferreira R, Bernardino L, Brito MA. Cellular response of the blood-brain barrier
284 to injury: Potential biomarkers and therapeutic targets for brain regeneration. *Neurobiology of*
285 *disease*. 2016;91:262-73. Epub 2016/03/22.
- 286 22. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al. Bone marrow origin of
287 endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological
288 neovascularization. *Circulation research*. 1999;85(3):221-8. Epub 1999/08/07.
- 289 23. Huang X, Li M, Zhou D, Deng Z, Guo J, Huang H. Endothelial progenitor cell transplantation
290 restores vascular injury in mice after whole-brain irradiation. *Brain research*. 2020;1746:147005. Epub
291 2020/07/06.
- 292 24. Pietrzik CU, Busse T, Merriam DE, Weggen S, Koo EH. The cytoplasmic domain of the LDL
293 receptor-related protein regulates multiple steps in APP processing. *EMBO J*. 2002;21(21):5691-700.
- 294 25. Van Gool B, Storck SE, Reekmans SM, Lechat B, Gordts P, Pradier L, et al. LRP1 Has a
295 Predominant Role in Production over Clearance of Aβeta in a Mouse Model of Alzheimer's Disease.
296 *Molecular neurobiology*. 2019;56(10):7234-45. Epub 2019/04/21.
- 297 26. Meister S, Storck SE, Hameister E, Behl C, Weggen S, Clement AM, et al. Expression of the ALS-
298 causing variant hSOD1(G93A) leads to an impaired integrity and altered regulation of claudin-5
299 expression in an in vitro blood-spinal cord barrier model. *Journal of cerebral blood flow and*
300 *metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism*.
301 2015;35(7):1112-21.
- 302
- 303

Figures




Figure 1

Reduced levels of tight junction proteins and P-gp after *Lrp1* CNS endothelial loss. (A) Immunoblotting for occludin, and claudin 5 (B) cyclophilin A and (C) P-gp in isolated brain endothelial 1 cells and their relative abundance compared with β -actin (loading control) of 2-month-old *Lrp1*^{lox/lox};*Slco1c1-CreERT2* mice and *Lrp1*^{lox/lox} littermate controls. Mean \pm SEM, n = 3 isolates/group. Significance was determined by Student's t test




Figure 2

Enhanced MMP activity after *Lrp1* deletion increases permeability in cultured primary brain endothelial cells. (A) relative MMP activity, (B) transendothelial resistance and (C) ¹⁴C-inulin permeability of primary brain endothelial cells isolated from of 2-month-old *Lrp1*^{lox/lox}; *Slco1c1-CreERT2* mice and *Lrp1*^{lox/lox} littermate controls. Primary brain endothelial cells were cultivated on transwell inserts in the cellZcope device. Cell or supernatant were used for subsequent studies when confluent. Mean \pm SEM. B and C are data from 3 independent isolates. Significance was determined by Student's t test.




Figure 3

Enhanced BBB permeability after *Lrp1* CNS endothelial loss. (A) Immunoblotting and quantification for IgG in 3 μ L cell- and blood-free CSF and (B) brain water content (calculated as [wet weight–dry weight] \times 100/wet weight) in 20-month-old *Lrp1*^{lox/lox}; *Slco1c1-CreERT2* mice and *Lrp1*^{lox/lox} littermate controls. Mean \pm SEM, n= 4 (in A) and 7 (in B) mice/group. Significance was determined by Student's t test.




Figure 4

Reduced brain body and brain weight upon brain endothelial *Lrp1* deletion. (A) Brain (n=7+10 mice, left to right) and (B) body weight (n=8+11 mice, left to right) in 12-month-old *Lrp1*^{lox/lox}; *Slco1c1-CreERT2* mice and *Lrp1*^{lox/lox} littermate controls. Mean ± SEM. Significance was determined by Student's t test.